Information Center
Your Health. Your Family. Your Choice.
|
|
National Vaccine Information Center Your Health. Your Family. Your Choice. |
MedAlerts.org |
| Table |
 |   | |
| Age | Count | Percent |
| 3-5 Years | 5 | 0.49% |
| 6-17 Years | 25 | 2.44% |
| 18-29 Years | 56 | 5.47% |
| 30-39 Years | 97 | 9.47% |
| 40-49 Years | 129 | 12.6% |
| 50-59 Years | 177 | 17.29% |
| 60-64 Years | 108 | 10.55% |
| 65-79 Years | 229 | 22.36% |
| 80+ Years | 57 | 5.57% |
| Unknown | 141 | 13.77% |
| TOTAL | 1,024 | 100% |
| Case Details |
Administered by: Public Purchased by: ?
Life Threatening? Yes Write-up: Guillain Barre syndrome/AIDP event. Paresthesia and nerve pain developed in bilateral legs 4 hours after shot and progressed slowly for 4 days in intensity and area involved. Symptoms progressed distally to superior. On the 5th day symptoms progressed rapidly and involved bilateral legs up to the groin, left arm up to lateral shoulder, and right hand. I went to the hospital and was admitted to start IVIG treatment for Guillain Barre Syndrome/AIDP. | ||||||||||||||||
Administered by: Private Purchased by: ?
Life Threatening? No Write-up: Heart palpitations, tachycardia, PVCs and shortness of breath, fatigue, weakness started on Monday (1/4), worsened over next 2 days. Saw primary doctor on 1/7 who called paramedics to take me to the ER due to EKG results and increased work of breathing. ER doctor suspects mild guillain-barre reaction, I will be following up with cardiology and pulmonology as soon as possible as they were unable to determine exact cause or fix the issues. | ||||||||||||||||
Administered by: Private Purchased by: ?
Life Threatening? Yes Write-up: Patient presented to the emergency department with sensory loss and loss of reflexes, evaluated by neurology and diagnosed with Guillain- Barre Syndrome thought to be secondary to the Pfizer Covid Vaccine | ||||||||||||||||
Administered by: Unknown Purchased by: ?
Life Threatening? No Write-up: 2nd vaccine on Saturday. Sunday, burning feet, leg, thigh. Went to ER to check if it was cause by diabetes, was told its probably not Gulliam Barre. Still having the symptoms. Worsen when laying down, better with movement. | ||||||||||||||||
Administered by: Private Purchased by: ?
Life Threatening? Yes Write-up: The patient received her first Moderna COVID-19 vaccination on 12/29/2020. However the patient was diagnosed with a positive COVID-19 test on January 4, 2021. Patient complained of nausea, vomiting, back pain, and sharp chest pain. On January 13, the patient presented to the emergency department again with shortness of breath and sharp, stabbing left-sided chest pain radiating to her back and right side. Initial work up ruled out cardiac etiologies. CTA chest demonstrated COVID-19 pneumonia. The patient complained of bilateral lower extremity weakness which had been progressing since her COVID-19 vaccination, per patient report. However, during her hospitalization the patient''s bilateral lower extremity weakness began to accelerate. On the 13th, the patient was able to ambulate to and from the bathroom herself. Then on January 14 the patient required maximum assistance. Neurology was consulted and work up initiated for suspected possible Guillain-Barr? syndrome (GBS) secondary to recent COVID-19 infection. On January 15, 2021, the patient became obtunded and unable to protect airway. She was emergently intubated for acute hypercapnic respiratory failure secondary to GBS. Neurology started GBS treatment with IVIG. Patient also developed NSTEMI and Takotsubo cardiomyopathy. Patient remains critically ill requiring mechanical ventilation. | ||||||||||||||||
Administered by: Military Purchased by: ?
Life Threatening? Yes Write-up: Patient developed symptoms of Guillain-Barre syndrome on January 15, 2021 and was admitted the Hospital. She was diagnosed and eventually required ICU level care and has been treated with plasmapheresis. She is currently still in the ICU but is stable. | ||||||||||||||||
Administered by: Private Purchased by: ?
Life Threatening? No Write-up: Employee received first dose of Pfizer-BioNTech Covid-19 Vaccine on 12/28/20. Per Employee''s manager: Patient began experiencing symptoms of neuropathy and was admitted to the hospital as an inpatient on 1/18/21. Informed from neurologist that most likely Guillain-Barr? syndrome resulted from vaccine and instructed to not receive 2nd dose of vaccine at this time. | ||||||||||||||||
Administered by: Private Purchased by: ?
Life Threatening? No Write-up: Patient admitted to hospital for progressive bilateral lower extremity weakness, sensory changes and inability to ambulate. Neuroimaging with significant degenerative disc disease with disc protrusions throughout the lumbar spine, greatest L3-L4, and with severe central stenosis. Question of radiculopathy vs peripheral neuropathy at admission, but no acute findings such as cauda equina syndrome. EMG consistent with atypical variant of GBS--acute motor sensory axonal neuropathy. | ||||||||||||||||
Administered by: Private Purchased by: ?
Life Threatening? No Write-up: Reports he has been diagnosed with Guillain Barre syndrome. Symptoms started with 2 fingers tingling 1/11/21. Progressively increasing in severity. Now has numb fingers and toes. Initiating IV therapy 1/22/21. | ||||||||||||||||
Administered by: Work Purchased by: ?
Life Threatening? No Write-up: Acute sensory-motor neuropathy symptoms. Appears consistent with a mild Gullian Barre Syndrome | ||||||||||||||||
Link To This Search Result:
https://medalerts.org/vaersdb/findfield.php?TABLE=ON&GROUP1=AGE&EVENTS=ON&SYMPTOMS=Guillain-Barre+syndrome+%2810018767%29&VAX=COVID19&STATE=NOTFR
Copyright ©
2024 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166